

# New Mitochondrial Function Assay Technology

Lawrence A. Wiater, Kyle O'Hollaren, Xiang-He Lei, and Barry R. Bochner  
Biolog, Inc. Hayward, CA, USA




## Abstract

We have developed a new mitochondrial function assay technology that measures the rates of metabolism of mitochondrial substrates and the sensitivity of metabolism of these substrates to mitochondrial inhibitors. The technology employs saponin permeabilized cells and a redox dye added to 96-well microplates that contain mitochondrial substrates or inhibitors precoated and dried into the wells. The MitoPlate S-1™ has a triplicate repeat of a set of 31 substrates. Mitochondrial function is assayed by measuring the rates of dye reduction from electrons flowing into and through the electron transport chain from substrates whose oxidation produces NADH (e.g., L-malate) or FADH<sub>2</sub> (e.g., succinate). The electrons donated to complex 1 or complex 2 travel to the distal portion of the electron transport chain where a tetrazolium redox dye (MC) acts as a terminal electron acceptor and changes from colorless to a purple formazan upon reduction. All 96 assays in the MitoPlate are run concurrently, and each assay provides different information because each substrate follows a different metabolic route using different transporters to enter the mitochondria, and then different dehydrogenases to produce NADH or FADH<sub>2</sub>. The MitoPlate S-1™ can also be used to assess the activity and specificity of substrate transport inhibitors, dehydrogenase inhibitors, or electron transport chain inhibitors. A second assay plate, the MitoPlate I-1™, provides another assessment of mitochondrial function by measuring the sensitivity of mitochondrial electron flow to a set of 22 diverse inhibitors titrated at 4 dilutions. The I-1 plates can be run using any of the NADH or FADH<sub>2</sub> producing substrates, each providing additional information. Using these new assays we show that the mitochondria from different cell types exhibit different functional properties. This new technology will assist efforts to understand how mitochondria change in cell models of human disorders that have a mitochondrial basis.

## The Assay Technology


**Figure 1** outlines the simple assay protocol. 30 µl of a permeabilizing assay mix containing saponin and Redox Dye MC in isotonic buffer is pipetted into all wells and incubated at 37° C for 1 hour. To start the assay, 30 ul of a cell suspension in isotonic buffer is added to each well. The recommended cell density is 1,000,000 cells/ml resulting in 30,000 cells/well. To record the rates of dye reduction in the wells, the MitoPlate is loaded into the OmniLog, which reads at 5 minute intervals for 2 to 4 hours. For MitoPlate I-1 with 22 mitochondrial inhibitors, the permeabilizing assay mix also contains an NADH or FADH<sub>2</sub> producing substrate such as L-malate or succinate. **Figure 3 and 4** show, respectively, the test layout in the MitoPlate S-1 and the MitoPlate I-1.

**Figure 1.** The Assay Protocol.



## Assays and Results

**Figure 2.** With this assay technology, mitochondrial function is profiled in a new way by measuring the rates of dye reduction from electrons flowing into and through the electron transport chain from substrates whose oxidation produces NADH or FADH<sub>2</sub>.




**Figure 3.** The MitoPlate S-1 simultaneously assays the metabolic rates of potential NADH or FADH<sub>2</sub> producing substrates.

A1 No Substrate	A2 D-Glucose	A3 Glycerol	A4 D-Glucose-1-PHA	A5 No Substrate	A6 D-Glucose	A7 Glycerol	A8 D-Glucose-1-PHA	A9 No Substrate	A10 D-Glucose	A11 Glycerol	A12 D-Glucose-1-PHA
B1 D-Glycerol-3-PHA	B2 D-Glycerol-3-PHA	B3 D,L-Glycerol-3-PHA	B4 L-Lactic Acid	B5 D-Glycerol-3-PHA	B6 D-Glycerol-3-PHA	B7 D,L-Glycerol-3-PHA	B8 L-Lactic Acid	B9 D-Glycerol-3-PHA	B10 D-Glycerol-3-PHA	B11 D,L-Glycerol-3-PHA	B12 L-Lactic Acid
C1 Pyruvic Acid	C2 Citric Acid	C3 D,L-Succinic Acid	C4 cis-Acrolic Acid	C5 Pyruvic Acid	C6 Citric Acid	C7 D,L-Succinic Acid	C8 cis-Acrolic Acid	C9 Pyruvic Acid	C10 Citric Acid	C11 D,L-Succinic Acid	C12 cis-Acrolic Acid
D1 L-Amino-Glutamic Acid	D2 Succinic Acid	D3 Pyruvic Acid	D4 L-Malic Acid	D5 L-Amino-Glutamic Acid	D6 Succinic Acid	D7 Pyruvic Acid	D8 L-Malic Acid	D9 L-Amino-Glutamic Acid	D10 Succinic Acid	D11 Pyruvic Acid	D12 L-Malic Acid
E1 L-Amino-Butyric Acid	E2 D,L-β-Hydroxy-Butyric Acid	E3 L-Glutamic Acid	E4 L-Glutamine	E5 L-Amino-Butyric Acid	E6 D,L-β-Hydroxy-Butyric Acid	E7 L-Glutamic Acid	E8 L-Glutamine	E9 L-Amino-Butyric Acid	E10 D,L-β-Hydroxy-Butyric Acid	E11 L-Glutamic Acid	E12 L-Glutamine
F1 α-Glc	F2 β-Glc	F3 α-Glc	F4 Fructose	F5 α-Glc	F6 β-Glc	F7 α-Glc	F8 Fructose	F9 α-Glc	F10 β-Glc	F11 α-Glc	F12 Fructose
G1 Malic Acid (DMH)	G2 Acetyl-L-Carnitine (DMH)	G3 Carnitine (DMH)	G4 Palmitoyl-DL-Carnitine (DMH)	G5 Malic Acid (DMH)	G6 Acetyl-L-Carnitine (DMH)	G7 Carnitine (DMH)	G8 Palmitoyl-DL-Carnitine (DMH)	G9 Malic Acid (DMH)	G10 Acetyl-L-Carnitine (DMH)	G11 Carnitine (DMH)	G12 Palmitoyl-DL-Carnitine (DMH)
H1 Pyruvic Acid (DMH)	H2 L-Amino-Butyric Acid (DMH)	H3 L-Amino-Isopropyl Acid (DMH)	H4 L-Lactic Acid (DMH)	H5 Pyruvic Acid (DMH)	H6 L-Amino-Butyric Acid (DMH)	H7 L-Amino-Isopropyl Acid (DMH)	H8 L-Lactic Acid (DMH)	H9 Pyruvic Acid (DMH)	H10 L-Amino-Butyric Acid (DMH)	H11 L-Amino-Isopropyl Acid (DMH)	H12 L-Lactic Acid (DMH)

**Figure 4.** The MitoPlate I-1 simultaneously assays the sensitivity of NADH or FADH<sub>2</sub> producing pathways to 22 mitochondrial inhibitors.



A1 No inhibitor	A2 No inhibitor	A3 No inhibitor	A4 No inhibitor	A5 No inhibitor	A6 No inhibitor	A7 No inhibitor	A8 No inhibitor	A9 No inhibitor	A10 No inhibitor	A11 No inhibitor	A12 No inhibitor
B1 Complex I Inhibitor Rotenone	B2 Complex I Inhibitor Rotenone	B3 Complex I Inhibitor Rotenone	B4 Complex I Inhibitor Rotenone	B5 Complex I Inhibitor Rotenone	B6 Complex I Inhibitor Rotenone	B7 Complex I Inhibitor Rotenone	B8 Complex I Inhibitor Rotenone	B9 Complex I Inhibitor Rotenone	B10 Complex I Inhibitor Rotenone	B11 Complex I Inhibitor Rotenone	B12 Complex I Inhibitor Rotenone
C1 Complex II Inhibitor Malonate	C2 Complex II Inhibitor Malonate	C3 Complex II Inhibitor Malonate	C4 Complex II Inhibitor Malonate	C5 Complex II Inhibitor Malonate	C6 Complex II Inhibitor Malonate	C7 Complex II Inhibitor Malonate	C8 Complex II Inhibitor Malonate	C9 Complex II Inhibitor Malonate	C10 Complex II Inhibitor Malonate	C11 Complex II Inhibitor Malonate	C12 Complex II Inhibitor Malonate
D1 Complex III Inhibitor Antimycin A	D2 Complex III Inhibitor Antimycin A	D3 Complex III Inhibitor Antimycin A	D4 Complex III Inhibitor Antimycin A	D5 Complex III Inhibitor Antimycin A	D6 Complex III Inhibitor Antimycin A	D7 Complex III Inhibitor Antimycin A	D8 Complex III Inhibitor Antimycin A	D9 Complex III Inhibitor Antimycin A	D10 Complex III Inhibitor Antimycin A	D11 Complex III Inhibitor Antimycin A	D12 Complex III Inhibitor Antimycin A
E1 Transporter FCCP	E2 Transporter FCCP	E3 Transporter FCCP	E4 Transporter FCCP	E5 Transporter FCCP	E6 Transporter FCCP	E7 Transporter FCCP	E8 Transporter FCCP	E9 Transporter FCCP	E10 Transporter FCCP	E11 Transporter FCCP	E12 Transporter FCCP
F1 Transporter Valproic Acid	F2 Transporter Valproic Acid	F3 Transporter Valproic Acid	F4 Transporter Valproic Acid	F5 Transporter Valproic Acid	F6 Transporter Valproic Acid	F7 Transporter Valproic Acid	F8 Transporter Valproic Acid	F9 Transporter Valproic Acid	F10 Transporter Valproic Acid	F11 Transporter Valproic Acid	F12 Transporter Valproic Acid
G1 Complex II Inhibitor Malonate	G2 Complex II Inhibitor Malonate	G3 Complex II Inhibitor Malonate	G4 Complex II Inhibitor Malonate	G5 Complex II Inhibitor Malonate	G6 Complex II Inhibitor Malonate	G7 Complex II Inhibitor Malonate	G8 Complex II Inhibitor Malonate	G9 Complex II Inhibitor Malonate	G10 Complex II Inhibitor Malonate	G11 Complex II Inhibitor Malonate	G12 Complex II Inhibitor Malonate
H1 Polyanion II	H2 Polyanion II	H3 Polyanion II	H4 Polyanion II	H5 Polyanion II	H6 Polyanion II	H7 Polyanion II	H8 Polyanion II	H9 Polyanion II	H10 Polyanion II	H11 Polyanion II	H12 Polyanion II

**Figure 5.** Colon and liver cells were assayed for substrate metabolism using the MitoPlate S-1. Four major differences were found in their metabolism.



**Figure 6.** Colon cells were assayed in MitoPlate I-1 with L-malate as the substrate. The cells were sensitive to Complex 1 and 3 inhibitors, but not Complex 2 inhibitors.

**Figure 7.** Colon cells were assayed in MitoPlate I-1 with succinate as the substrate. The cells were sensitive to Complex 2 and 3 inhibitors, but not Complex 1 inhibitors.



## Conclusions

The MitoPlate assay technology enables profiling of mitochondrial function in much greater detail. The MitoPlates have 53 phenotypic assays already dried in the wells, so they can be tested at the same time by simply inoculating with a cell suspension. The assays are colorimetric and can be performed using any kinetic microplate reader. The technology provides a simple and highly sensitive discovery tool for mitochondrial researchers.